Townsend Scott B Form 3 August 16, 2012

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

Townsend Scott B

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

08/15/2012

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

AMAG PHARMACEUTICALS INC. [AMAG]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O AMAG

PHARMACEUTICALS,

INC., 100 HAYDEN AVENUE

(Street)

10% Owner Director Other

(Check all applicable)

_X__ Officer (give title below) (specify below) SVP, General Counsel

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

LEXINGTON, MAÂ 02421

(City) (State) (Zip)

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial Ownership

Form: (Instr. 5) Direct (D) or Indirect

(I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

Exercisable

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

4. 5. Conversion or Exercise

Price of

6. Nature of Indirect Ownership Beneficial Ownership Form of (Instr. 5)

Expiration

Date

Title

Amount or Number of

Security: Derivative Security Direct (D)

Derivative

1

Edgar Filing: Townsend Scott B - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Stock Options	(1)	08/15/2022	Common Stock	52,500	\$ 14.99	D	Â
Restricted Stock Units	(2)	(3)	Common	17,500	\$ <u>(4)</u>	D	Â

Reporting Owners

Reporting Owner Name / Address			Relationships		
	Director	10% Owner	Officer	Other	
Townsend Scott B					
C/O AMAG PHARMACEUTICALS, INC.	â	â	SVP, General Counsel	â	
100 HAYDEN AVENUE	А	A	A SVP, General Counsel	А	
LEXINGTON, MA 02421					

Signatures

Nancy R. Smith, attorney-in-fact

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant will vest in four equal installments on August 15, 2013, August 15, 2014, August 15, 2015 and August 15, 2016.
- (2) Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant will vest in four equal installments on August 15, 2013, August 15, 2014, August 15, 2015 and August 15, 2016.
- (3) Not applicable.
- (4) Each restricted stock unit represents a contingent right to receive one share of common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2